Merck: licensing charges in the earnings bridge
Merck guides non-GAAP EPS to $2.77–$2.82 and identifies a $0.12-per-share SciBrunch licensing charge. This keeps development-asset economics in the financial evidence trail.
Merck & Co. / MRKPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
- $2.80 is a proposed cent-level hurdle, not the exact $2.795 guidance midpoint.
Primary evidence
Reporting date unconfirmed — research candidate
Merck Q3 2026 results and outlookPublished 2026-10-29
Potential outcome market
Will Merck 2026 non-GAAP diluted EPS exceed $2.80?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.